Genmab — Maj 2021
-
The EU CT Register shows two clinical for Mim8 https://www.clinicaltrialsregister.eu/ctr-search/search?query=Mim8
-
Spørgsmåll til Q&A er meget velkommen.
-
Genmab
Genmab 32,624 followers 1d • Edited •
1 day ago
During today's The New York Academy of Sciences virtual symposium, A Kate Sasser, Senior VP, Head of Translation Research will be speaking at 3:55 PM EST on the Frontiers in Cancer Immunotherapy. Join Kate and other industry thought leaders at https://lnkd.in/gq4XRyZ -
Servicemeddelelse. Efter lang tids analyse, gennemgang og omkodning i et 12 år gammelt maskinrum tror vi, at
uploadsproblemet i debatten er tæt på en løsning. Kør endelig løs og meld tilbage ved evt. fejl. -
Langers Skarpe: Sektorrotation holder markedet oppe https://www.proinvestor.com/investornyt/675083/langers-skarpe-sektorrotation-holder-markedet-oppe
-
Kursgraf: Efter en positiv fredag er der igen mulighed for et teknisk brud op i biotek sektoren.
https://www.proinvestor.com/investornyt/675086/us-biotech-korer-vandret-pa-tredje-maned -
God morgen.
-
Asien: Stærkt blandede markeder - kursfald i Tokyo https://www.proinvestor.com/investornyt/675092/asien-staerkt-blandede-markeder-kursfald-i-tokyo
-
Mandagens aviser med ISS, TDC og Novo Nordisk https://www.proinvestor.com/investornyt/675091/mandagens-aviser-med-iss-tdc-og-novo-nordisk
-
Vi mangler stadig flere spørgsmål til Q&A.
-
-
God morgen .
-
Genmab har fået et nyt kursmål, efter at JPMorgan har løftet sit kursmål til 2500 kr. fra 2350 kr. Genmab-aktien steg onsdag 0,1 pct. til 2231 kr.: https://www.proinvestor.com/investornyt/675102/aktier-tendens-maersk-og-ambu-indtager-hovedroller-i-positivt-marked
-
God formiddag
-
Flot Stockbull.
-
Aktier/åbning: Ambu, Genmab og Ørsted til tops i grøn åbning https://www.proinvestor.com/investornyt/675107/aktier-abning-ambu-genmab-og-orsted-til-tops-i-gron-abning
-
17.5.2021 10.34 · GlobeNewswire
Transactions in connection with share buy-back program
Company AnnouncementCOPENHAGEN, Denmark; May17, 2021 – Genmab A/S (Nasdaq: GMAB). On February 23, 2021 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant exercises and to honor our commitments under our Restricted Stock Units program.
The share buy-back program is expected to be completed no later than June 30, 2021 and comprises up to 200,000 shares....
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind